{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:08:37Z","timestamp":1789427317795,"version":"build-2803163510"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T00:00:00Z","timestamp":1751760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T00:00:00Z","timestamp":1751760000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1245\/s10434-025-17710-1","type":"journal-article","created":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T17:46:41Z","timestamp":1751824001000},"page":"7860-7873","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cytotoxic Anti-tumor Drugs and Tumor-Associated Macrophages Synergistically Surge PD-L1 Expression in Esophageal Squamous Cell Carcinoma"],"prefix":"10.1245","volume":"32","author":[{"given":"Kosuke","family":"Hirose","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Otsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Saeki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Tobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyotaka","family":"Hosoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihiro","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanari","family":"Tatsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiko","family":"Ikehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ofuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoharu","family":"Nakanoko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Oki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoharu","family":"Yoshizumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koshi","family":"Mimori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,6]]},"reference":[{"key":"17710_CR1","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","volume":"11","author":"Y Ishida","year":"1992","unstructured":"Ishida Y, Agata Y, Shibahara K, et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992;11:3887\u201395.","journal-title":"EMBO J."},{"key":"17710_CR2","doi-asserted-by":"crossref","first-page":"12293","DOI":"10.1073\/pnas.192461099","volume":"17","author":"Y Iwai","year":"2002","unstructured":"Iwai Y, Ishida M, Tanaka Y, et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA. 2002;17:12293\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"17710_CR3","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568\u201371.","journal-title":"Nature."},{"key":"17710_CR4","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.molcel.2019.09.030","volume":"76","author":"JH Cha","year":"2019","unstructured":"Cha JH, Chan LC, Li CW, et al. Mechanisms controlling PD-L1 expression in cancer. Mol Cell. 2019;76:359\u201370.","journal-title":"Mol Cell."},{"key":"17710_CR5","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","volume":"8","author":"H Dong","year":"2002","unstructured":"Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7\u2013H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8:793\u2013800.","journal-title":"Nat Med."},{"key":"17710_CR6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","volume":"11","author":"H Nishimura","year":"1999","unstructured":"Nishimura H, Nose M, Hiai H, et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999;11:141\u201351.","journal-title":"Immunity."},{"key":"17710_CR7","first-page":"61","volume":"36","author":"S Saraf","year":"2017","unstructured":"Saraf S, Koshiji M, Lunceford J, et al. Safety and antitumor activity of the anti\u2013programmed death-1 antibody pembrolizumab in patients with advanced esophageal carcinoma. J Clin Oncol. 2017;36:61\u20137.","journal-title":"J Clin Oncol."},{"key":"17710_CR8","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S1470-2045(19)30626-6","volume":"20","author":"K Kato","year":"2019","unstructured":"Kato K, Cho BC, Takahashi M, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20:1506\u201317.","journal-title":"Lancet Oncol."},{"key":"17710_CR9","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","volume":"377","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377:2500\u20131.","journal-title":"N Engl J Med."},{"key":"17710_CR10","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/PAI.0000000000000408","volume":"24","author":"C Roach","year":"2016","unstructured":"Roach C, Zhang N, Corigliano E, et al. Development of a companion diagnostic PD-L1 immunohistochemistry assay for pembrolizumab therapy in non-small-cell lung cancer. Appl Immunohistochem Mol Morphol. 2016;24:392\u20137.","journal-title":"Appl Immunohistochem Mol Morphol."},{"key":"17710_CR11","doi-asserted-by":"crossref","first-page":"330","DOI":"10.5858\/arpa.2018-0043-OA","volume":"143","author":"K Kulangara","year":"2019","unstructured":"Kulangara K, Zhang N, Corigliano E, et al. Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer. Arch Pathol Lab Med. 2019;143:330\u20137.","journal-title":"Arch Pathol Lab Med."},{"key":"17710_CR12","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","volume":"14","author":"SP Patel","year":"2015","unstructured":"Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015;14:847\u201356.","journal-title":"Mol Cancer Ther."},{"key":"17710_CR13","doi-asserted-by":"crossref","unstructured":"Zou W, Wolchok JD, Chen L. PD-L1 ( B7-H1 ) and PD-1 pathway blockade for cancer therapy\u202f: mechanisms , response biomarkers , and combinations. Sci Trans. 2016;8:328rv4.","DOI":"10.1126\/scitranslmed.aad7118"},{"key":"17710_CR14","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.21873\/anticanres.12662","volume":"38","author":"M Bassanelli","year":"2018","unstructured":"Bassanelli M, Sioletic S, Martini M, et al. Heterogeneity of PD-L1 expression and relationship with biology of NSCLC. Anticancer Res. 2018;38:3789\u201396.","journal-title":"Anticancer Res."},{"key":"17710_CR15","doi-asserted-by":"crossref","first-page":"e0186192","DOI":"10.1371\/journal.pone.0186192","volume":"12","author":"S Nakamura","year":"2017","unstructured":"Nakamura S, Hayashi K, Imaoka Y, et al. Intratumoral heterogeneity of programmed cell death ligand-1 expression is common in lung cancer. PLoS One. 2017;12:e0186192.","journal-title":"PLoS One."},{"key":"17710_CR16","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/annonc\/mdv489","volume":"27","author":"M Ilie","year":"2016","unstructured":"Ilie M, Long-Mira E, Bence C, et al. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Ann Oncol. 2016;27:147\u201353.","journal-title":"Ann Oncol."},{"issue":"6257","key":"17710_CR17","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1126\/science.aad4140","volume":"350","author":"MM Gubin","year":"2015","unstructured":"Gubin MM, Schreiber RD. The odds of immunotherapy success. Science. 2015;350(6257):158\u20139.","journal-title":"Science"},{"key":"17710_CR18","doi-asserted-by":"crossref","first-page":"R48","DOI":"10.1186\/bcr2605","volume":"12","author":"H Ghebeh","year":"2010","unstructured":"Ghebeh H, Lehe C, Barhoush E, et al. Doxorubicin downregulates cell surface B7\u2013H1 expression and upregulates its nuclear expression in breast cancer cells\u202f: role of B7\u2013H1 as an anti-apoptotic molecule. Breast Cancer Res. 2010;12:R48.","journal-title":"Breast Cancer Res."},{"key":"17710_CR19","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1158\/0008-5472.CAN-14-3098","volume":"75","author":"J Peng","year":"2015","unstructured":"Peng J, Hamanishi J, Matsumura N, et al. Chemotherapy induces programmed cell death-ligand 1 overexpression via the nuclear factor-\u03baBto foster an immunosuppressive tumor microenvironment in ovarian cancer. Cancer Res. 2015;75:5034\u201345.","journal-title":"Cancer Res."},{"key":"17710_CR20","doi-asserted-by":"crossref","first-page":"20090","DOI":"10.1038\/srep20090","volume":"6","author":"J Sheng","year":"2016","unstructured":"Sheng J, Fang W, Yu J, et al. Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer. Sci Rep. 2016;6:20090.","journal-title":"Sci Rep."},{"issue":"2","key":"17710_CR21","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3892\/or.2015.4435","volume":"35","author":"C Leng","year":"2016","unstructured":"Leng C, Li Y, Qin J, Ma J, Liu X, Cui Y, Wang Q. Relationship between expression of PD-L1 and PD-L2 on esophageal squamous cell carcinoma and the antitumor effects of CD8+ T cells. Oncol Rep. 2016;35(2):699\u2013708.","journal-title":"Oncol Rep"},{"key":"17710_CR22","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"Rha SY, Oh DY, Ya\u00f1ez P, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24:1181\u201395.","journal-title":"Lancet Oncol."},{"key":"17710_CR23","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","volume":"14","author":"A Mantovani","year":"2017","unstructured":"Mantovani A, Marchesi F, Malesci A, et al. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017;14:399\u2013416.","journal-title":"Nat Rev Clin Oncol."},{"key":"17710_CR24","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.semcancer.2008.03.004","volume":"18","author":"SK Biswas","year":"2008","unstructured":"Biswas SK, Mantovani A, Larghi P, et al. Macrophage polarization in tumour progression. Semin Cancer Biol. 2008;18:349\u201355.","journal-title":"Semin Cancer Biol."},{"key":"17710_CR25","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3390\/ijms22137239","volume":"22","author":"P Moeini","year":"2021","unstructured":"Moeini P, Nied\u017awiedzka-Rystwej P. Tumor-associated macrophages: combination of therapies, the approach to improve cancer treatment. Int J Mol Sci. 2021;22:30\u20133.","journal-title":"Int J Mol Sci."},{"key":"17710_CR26","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/imr.12603","volume":"280","author":"S Saha","year":"2017","unstructured":"Saha S, Shalova IN, Biswas SK. Metabolic regulation of macrophage phenotype and function. Immunol Rev. 2017;280:102\u201311.","journal-title":"Immunol Rev."},{"key":"17710_CR27","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.addr.2017.04.010","volume":"114","author":"C Ngambenjawong","year":"2017","unstructured":"Ngambenjawong C, Gustafson HH, Pun SH. Progress in tumor-associated macrophage (TAM)-targeted therapeutics. Adv Drug Deliv Rev. 2017;114:206\u201321.","journal-title":"Adv Drug Deliv Rev."},{"key":"17710_CR28","doi-asserted-by":"crossref","first-page":"R246","DOI":"10.1016\/j.cub.2020.01.031","volume":"30","author":"L Cassetta","year":"2020","unstructured":"Cassetta L, Pollard JW. Tumor-associated macrophages. Curr Biol. 2020;30:R246\u20138.","journal-title":"Curr Biol."},{"key":"17710_CR29","first-page":"1","volume":"6","author":"L Ch\u00e1vez-Gal\u00e1n","year":"2015","unstructured":"Ch\u00e1vez-Gal\u00e1n L, Olleros ML, Vesin D, et al. Much more than M1 and M2 macrophages, there are also CD169+ and TCR+ macrophages. Front Immunol. 2015;6:1\u201315.","journal-title":"Front Immunol."},{"key":"17710_CR30","first-page":"1","volume":"9","author":"C Li","year":"2021","unstructured":"Li C, Xu X, Wei S, et al. Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer. J Immunother Cancer. 2021;9:1\u201322.","journal-title":"J Immunother Cancer."},{"key":"17710_CR31","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1093\/neuonc\/nox081","volume":"19","author":"C Zhu","year":"2017","unstructured":"Zhu C, Kros JM, Cheng C, et al. The contribution of tumor-associated macrophages in glioma neo-angiogenesis and implications for anti-angiogenic strategies. Neuro Oncol. 2017;19:1435\u201346.","journal-title":"Neuro Oncol."},{"key":"17710_CR32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-018-0930-x","volume":"18","author":"X Jiang","year":"2019","unstructured":"Jiang X, Wang J, Deng X, et al. Role of the tumor microenvironment in PD-L1\/PD-1-mediated tumor immune escape. Mol Cancer. 2019;18:1\u201317.","journal-title":"Mol Cancer."},{"key":"17710_CR33","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1111\/1759-7714.14108","volume":"12","author":"Y Li","year":"2021","unstructured":"Li Y, Liu H, Zhao Y, et al. Tumor-associated macrophages (TAMs)-derived osteopontin (OPN) upregulates PD-L1 expression and predicts poor prognosis in non-small cell lung cancer (NSCLC). Thorac Cancer. 2021;12:2698\u2013709.","journal-title":"Thorac Cancer."},{"key":"17710_CR34","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/cas.13237","volume":"108","author":"S Tsutsumi","year":"2017","unstructured":"Tsutsumi S, Saeki H, Nakashima Y, et al. Programmed death-ligand 1 expression at tumor invasive front is associated with epithelial-mesenchymal transition and poor prognosis in esophageal squamous cell carcinoma. Cancer Sci. 2017;108:1119\u201327.","journal-title":"Cancer Sci."},{"key":"17710_CR35","doi-asserted-by":"crossref","first-page":"71455","DOI":"10.18632\/oncotarget.12213","volume":"7","author":"Y Zhu","year":"2016","unstructured":"Zhu Y, Li M, Mu D, et al. CD8 + \/ FOXP3 + ratio and PD-L1 expression associated with survival in pT3N0M0 stage esophageal squamous cell cancer. Oncotarget. 2016;7:71455\u201365.","journal-title":"Oncotarget."},{"key":"17710_CR36","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.21037\/jtd.2016.11.01","volume":"8","author":"H-X Qu","year":"2016","unstructured":"Qu H-X, Zhao L-P, Zhan S-H, et al. Clinicopathological and prognostic significance of programmed cell death ligand 1 (PD-L1) expression in patients with esophageal squamous cell carcinoma: a meta-analysis. J Thorac Dis. 2016;8:3197\u2013204.","journal-title":"J Thorac Dis."},{"key":"17710_CR37","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.athoracsur.2010.12.041","volume":"91","author":"M Loos","year":"2011","unstructured":"Loos M, Langer R, Schuster T, et al. Clinical significance of the costimulatory molecule B7\u2013H1 in barrett carcinoma. Ann Thorac Surg. 2011;91:1025\u201331.","journal-title":"Ann Thorac Surg."},{"key":"17710_CR38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2015.09.019","volume":"52","author":"SH Lim","year":"2016","unstructured":"Lim SH, Hong M, Ahn S, et al. Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer. Eur J Cancer. 2016;52:1\u20139.","journal-title":"Eur J Cancer."},{"key":"17710_CR39","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.5858\/arpa.2015-0544-OA","volume":"140","author":"M Dolled-Filhart","year":"2016","unstructured":"Dolled-Filhart M, Locke D, Murphy T, et al. Development of a prototype immunohistochemistry assay to measure programmed death ligand-1 expression in tumor tissue. Arch Pathol Lab Med. 2016;140:1259\u201366.","journal-title":"Arch Pathol Lab Med."},{"key":"17710_CR40","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.5858\/arpa.2015-0542-OA","volume":"140","author":"M Dolled-Filhart","year":"2016","unstructured":"Dolled-Filhart M, Roach C, Toland G, et al. Development of a companion diagnostic for pembrolizumab in non-small cell lung cancer using immunohistochemistry for programmed death ligand-1. Arch Pathol Lab Med. 2016;140:1243\u20139.","journal-title":"Arch Pathol Lab Med."},{"key":"17710_CR41","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1245\/s10434-016-5376-z","volume":"23","author":"S Ito","year":"2016","unstructured":"Ito S, Okano S, Morita M, et al. Expression of PD-L1 and HLA class I in esophageal squamous cell carcinoma: prognostic factors for patient outcome. Ann Surg Oncol. 2016;23:508\u201315.","journal-title":"Ann Surg Oncol."},{"key":"17710_CR42","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1111\/cas.13072","volume":"107","author":"P Zhang","year":"2016","unstructured":"Zhang P, Ma Y, Lv C, et al. Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy. Cancer Sci. 2016;107:1563\u201371.","journal-title":"Cancer Sci."},{"key":"17710_CR43","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/ijc.31107","volume":"142","author":"S Korehisa","year":"2018","unstructured":"Korehisa S, Oki E, Iimori M, et al. Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability. Int J Cancer. 2018;142:822\u201332.","journal-title":"Int J Cancer."},{"key":"17710_CR44","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.yexcr.2017.08.028","volume":"359","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Du W, Chen Z, et al. Upregulation of PD-L1 by SPP1 mediates macrophage polarization and facilitates immune escape in lung adenocarcinoma. Exp Cell Res. 2017;359:449\u201357.","journal-title":"Exp Cell Res."},{"key":"17710_CR45","first-page":"1","volume":"13","author":"T Zhang","year":"2022","unstructured":"Zhang T, Yu H, Dai X, et al. CMTM6 and CMTM4 as two novel regulators of PD-L1 modulate the tumor microenvironment. Front Immunol. 2022;13:1\u201311.","journal-title":"Front Immunol."},{"key":"17710_CR46","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.21873\/anticanres.11574","volume":"37","author":"K Sato","year":"2017","unstructured":"Sato K, Masuda T, Hu Q, et al. Phosphoserine phosphatase is a novel prognostic biomarker on chromosome 7 in colorectal cancer. Anticancer Res. 2017;37:2365\u201371.","journal-title":"Anticancer Res."},{"key":"17710_CR47","doi-asserted-by":"crossref","first-page":"133","DOI":"10.7150\/ijbs.14242","volume":"12","author":"T Masuda","year":"2016","unstructured":"Masuda T, Xu X, Dimitriadis EK, et al. \u201cDNA binding region\u201c of BRCA1 affects genetic stability through modulating the intra-S-phase checkpoint. Int J Biol Sci. 2016;12:133\u201343.","journal-title":"Int J Biol Sci."},{"key":"17710_CR48","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1001\/jamaoncol.2015.3638","volume":"2","author":"J McLaughlin","year":"2016","unstructured":"McLaughlin J, Han G, Schalper K, et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non-small cell lung cancer (NSCLC). JAMA Oncol. 2016;2:46\u201354.","journal-title":"JAMA Oncol."},{"key":"17710_CR49","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/modpathol.2016.186","volume":"30","author":"JA Rehman","year":"2017","unstructured":"Rehman JA, Han G, Carvajal-hausdorf DE, et al. Quantitative and pathologist-read comparison of the heterogeneity of programmed cell lung cancer. Mod Pathol. 2017;30:340\u20139.","journal-title":"Mod Pathol."},{"key":"17710_CR50","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.cllc.2017.04.014","volume":"18","author":"D Casadevall","year":"2017","unstructured":"Casadevall D, Clav\u00e9 S, Taus \u00c1, et al. Heterogeneity of tumor and immune cell PD-L1 expression and lymphocyte counts in surgical. Clin Lung Cancer. 2017;18:682\u201391.","journal-title":"Clin Lung Cancer."},{"key":"17710_CR51","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00262-017-1982-2","volume":"66","author":"B Dislich","year":"2017","unstructured":"Dislich B, Stein A, Seiler CA, et al. Expression patterns of programmed death-ligand 1 in esophageal adenocarcinomas\u202f: comparison between primary tumors and metastases. Cancer Immunol Immunother. 2017;66:777\u201386.","journal-title":"Cancer Immunol Immunother."},{"key":"17710_CR52","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejca.2019.01.018","volume":"111","author":"T Yagi","year":"2019","unstructured":"Yagi T, Baba Y, Okadome K, et al. Tumour-associated macrophages are associated with poor prognosis and programmed death ligand 1 expression in oesophageal cancer. Eur J Cancer. 2019;111:38\u201349.","journal-title":"Eur J Cancer."},{"key":"17710_CR53","doi-asserted-by":"crossref","first-page":"874589","DOI":"10.3389\/fimmu.2022.874589","volume":"13","author":"Y Pu","year":"2022","unstructured":"Pu Y, Ji Q. Tumor-associated macrophages regulate PD-1 \/ PD-L1 immunosuppression. Front Immunol. 2022;13:874589.","journal-title":"Front Immunol."},{"key":"17710_CR54","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.7150\/thno.73152","volume":"12","author":"Z Ma","year":"2022","unstructured":"Ma Z, Zhang W, Dong B, et al. Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitorbased immunotherapy. Theranostics. 2022;12:4965\u201379.","journal-title":"Theranostics."},{"key":"17710_CR55","first-page":"1","volume":"9","author":"Z Wang","year":"2021","unstructured":"Wang Z, Zhang X, Li W, et al. ATM\/NEMO signaling modulates the expression of PD-L1 following docetaxel chemotherapy in prostate cancer. J Immunother Cancer. 2021;9:1\u201314.","journal-title":"J Immunother Cancer."},{"key":"17710_CR56","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.3892\/or.2017.5894","volume":"38","author":"S Funaki","year":"2017","unstructured":"Funaki S, Shintani Y, Kawamura T, et al. Chemotherapy enhances programmed cell death 1\/ligand 1 expression via TGF-\u03b2 induced epithelial mesenchymal transition in non-small cell lung cancer. Oncol Rep. 2017;38:2277\u201384.","journal-title":"Oncol Rep."},{"key":"17710_CR57","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s40425-016-0163-8","volume":"4","author":"L Van Der Kraak","year":"2016","unstructured":"Van Der Kraak L, Goel G, Ramanan K, et al. 5-Fluorouracil upregulates cell surface B7\u2013H1 (PD-L1) expression in gastrointestinal cancers. J Immunother Cancer. 2016;4:65.","journal-title":"J Immunother Cancer."},{"key":"17710_CR58","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.tranon.2018.08.005","volume":"11","author":"HY Ng","year":"2018","unstructured":"Ng HY, Li J, Tao L, et al. Chemotherapeutic treatments increase PD-L1 expression in esophageal squamous cell carcinoma through EGFR\/ERK activation. Transl Oncol. 2018;11:1323\u201333.","journal-title":"Transl Oncol."},{"key":"17710_CR59","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.athoracsur.2016.12.011","volume":"103","author":"R Dhupar","year":"2017","unstructured":"Dhupar R, Van Der Kraak L, Pennathur A, et al. Targeting immune checkpoints in esophageal cancer\u202f: a high mutational load tumor. Ann Thorac Surg. 2017;103:1340\u20139.","journal-title":"Ann Thorac Surg."},{"key":"17710_CR60","first-page":"1","volume":"15","author":"M Demeule","year":"2024","unstructured":"Demeule M, Currie JC, Charfi C, et al. Sudocetaxel zendusortide (TH1902) triggers the cGAS\/STING pathway and potentiates anti-PD-L1 immune-mediated tumor cell killing. Front Immunol. 2024;15:1\u201320.","journal-title":"Front Immunol."},{"key":"17710_CR61","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0140-6736(24)00745-1","volume":"404","author":"K Kato","year":"2024","unstructured":"Kato K, Machida R, Ito Y, et al. A randomized controlled phase III trial comparing doublet chemotherapy, triplet chemotherapy, and doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced esophageal cancer: the JCOG1109 NExT study. Lancet. 2024;404:55\u201366.","journal-title":"Lancet."},{"key":"17710_CR62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-022-01396-z","volume":"16","author":"L Cai","year":"2023","unstructured":"Cai L, Li Y, Tan J, et al. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy. J Hematol Oncol. 2023;16:1\u201334.","journal-title":"J Hematol Oncol."},{"key":"17710_CR63","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41422-020-0343-4","volume":"30","author":"X He","year":"2020","unstructured":"He X, Xu C. Immune checkpoint signaling and cancer immunotherapy. Cell Res. 2020;30:660\u20139.","journal-title":"Cell Res."},{"key":"17710_CR64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2022.867260","volume":"13","author":"M Cutolo","year":"2022","unstructured":"Cutolo M, Campitiello R, Gotelli E, et al. The role of M1\/M2 macrophage polarization in rheumatoid arthritis synovitis. Front Immunol. 2022;13:1\u201314.","journal-title":"Front Immunol."},{"key":"17710_CR65","first-page":"1","volume":"14","author":"H Li","year":"2023","unstructured":"Li H, Miao Y, Zhong L, et al. Identification of TREM2-positive tumor-associated macrophages in esophageal squamous cell carcinoma: implication for poor prognosis and immunotherapy modulation. Front Immunol. 2023;14:1\u201315.","journal-title":"Front Immunol."},{"key":"17710_CR66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers14184374","volume":"14","author":"E Matsubara","year":"2022","unstructured":"Matsubara E, Komohara Y, Esumi S, et al. SPP1 derived from macrophages is associated with a worse clinical course and chemo-resistance in lung adenocarcinoma. Cancers (Basel). 2022;14:1\u201319.","journal-title":"Cancers (Basel)."},{"key":"17710_CR67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2019.00001","volume":"10","author":"Z Zong","year":"2019","unstructured":"Zong Z, Zou J, Mao R, et al. M1 macrophages induce PD-L1 expression in hepatocellular carcinoma cells through IL-1\u03b2 signaling. Front Immunol. 2019;10:1\u201312.","journal-title":"Front Immunol."},{"key":"17710_CR68","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1093\/annonc\/mdy086","volume":"29","author":"G Pasello","year":"2018","unstructured":"Pasello G, Zago G, Lunardi F, et al. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time. Ann Oncol. 2018;29:1258\u201365.","journal-title":"Ann Oncol."},{"key":"17710_CR69","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1158\/0008-5472.CAN-15-0255","volume":"75","author":"MWL Teng","year":"2015","unstructured":"Teng MWL, Ngiow SF, Ribas A, et al. Classifying cancers basedon T-cell infiltration and PD-L1. Cancer Res. 2015;75:2139\u201345.","journal-title":"Cancer Res."},{"key":"17710_CR70","doi-asserted-by":"crossref","unstructured":"Hsu C, Adenis A, Hajbi F El, et al. Nivolumab combination therapy in Advanced esophageal squamous-cell carcinoma. 2022;449\u2013462.","DOI":"10.1056\/NEJMoa2111380"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17710-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-17710-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17710-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T14:05:14Z","timestamp":1758549914000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-17710-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,6]]},"references-count":70,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["17710"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-17710-1","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,6]]},"assertion":[{"value":"3 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no commercial conflict of interest associated with this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}},{"value":"This study was approved by the Institutional Review Board of Kyushu University (approval no. #30-427 and #241319) and was conducted according to the ethical principles outlined in the Declaration of Helsinki. Informed consent was obtained through an opt-out method, as publicly disclosed on the institutional website (). Participants had the opportunity to decline participation, and no refusal was recorded.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}